| SLRX Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the SLRX shares outstanding history going back to 7/22/2019:
Also see: SLRX Market Cap History SLRX YTD Return |
SLRX Shares Outstanding History — Salarius Pharmaceuticals Share Count Over Time
As of 11/12/2025 Salarius Pharmaceuticals has 5.86 million SLRX shares outstanding. Investors often track the SLRX shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows SLRX share count trends over time, with 26 historical shares outstanding datapoints presented, dating back to 7/22/2019.
| SLRX Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
SLRX Historical Shares Outstanding: +394.92% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SLRX Stock Price Chart |
| About Decoy Therapeutics Inc |
| Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Co.'s lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. We show 26 historical shares outstanding datapoints in our coverage of SLRX's shares outstanding history. Understanding the changing numbers of SLRX shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like SLRX versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching SLRX by allowing them to research SLRX shares outstanding history as well as any other stock in our coverage universe. |
| SLRX Current Stock Quote |
Quotes delayed 20 minutes  Free SLRX Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| SLRX Share Performance |
| Shares Outstanding Peers |
| Salarius Pharmaceuticals (SLRX) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
SLS Shares Outstanding History SMLR Shares Outstanding History SMMT Shares Outstanding History SMTI Shares Outstanding History SNBP Shares Outstanding History SNCA Shares Outstanding History SNDA Shares Outstanding History SNDX Shares Outstanding History SNES Shares Outstanding History SNGX Shares Outstanding History More Healthcare companies » |
SLRX Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
